Skip to main content

CITIUS ONCOLOGY, INC.

For the period ended Mar 31, 2025. Filed May 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

CTOR$0.55+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

3.1Certificate of Incorporation of Citius Oncology, Inc. (incorporated by reference to Exhibit 3.1 of Form 8-K filed on August 16, 2024).
3.2Certificate of Amendment to Certificate of Incorporation of Citius Oncology, Inc., effective April 7, 2025 (incorporated by reference to Annex A to Schedule 14C filed on February 24, 2025).
31.1Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).*
31.2Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).*
32.1Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.*
EX-101.INSInline XBRL Instance Document*
EX-101.SCHInline XBRL Taxonomy Extension Schema Document*
EX-101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
EX-101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
EX-101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
EX-101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
EX-104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
*Filed herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.